Minimizing costs for treating deep vein thrombosis: the role for fondaparinux
ثبت نشده
چکیده
Modelling A decision tree model was created to capture the central issues in acute DVT treatment and to examine the costeffectiveness of fondaparinux for DVT therapy compared with enoxaparin. The model was based on various assumptions on efficacy, drug dosing and costs, which were all reported in the current study but are too numerous to be reported here. However, the authors reported that their model was biased against fondaparinux.
منابع مشابه
Extensive deep vein thrombosis treatment using fondaparinux and edoxaban: a case report
BACKGROUND Factor Xa inhibitor is a key drug in the coagulation cascade. Parenteral anticoagulation using low molecular weight heparin or fondaparinux is the recommended form of treatment for most patients presenting with venous thrombosis. Following the acute phase, edoxaban is recommended. We present a case of extensive deep vein thrombosis treated using fondaparinux and edoxaban. CASE PRES...
متن کاملFondaparinux for the treatment of superficial-vein thrombosis in the legs.
BACKGROUND The efficacy and safety of anticoagulant treatment for patients with acute, symptomatic superficial-vein thrombosis in the legs, but without concomitant deep-vein thrombosis or symptomatic pulmonary embolism at presentation, have not been established. METHODS In a randomized, double-blind trial, we assigned 3002 patients to receive either fondaparinux, administered subcutaneously a...
متن کاملThe cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery.
BACKGROUND The selective antithrombotic fondaparinux is more effective than the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism (deep-vein thrombosis [DVT] or pulmonary embolism) in patients undergoing major orthopedic surgery, but its cost-effectiveness is undetermined. OBJECTIVES To evaluate the cost-effectiveness of fondaparinux relative to enoxaparin as pr...
متن کاملSuperiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points.
STUDY OBJECTIVES To assess the relevance of various efficacy end points established for thromboprophylaxis trials, we compared the results of the fondaparinux phase III program in major orthopedic surgery using the original primary efficacy end point with those obtained when the efficacy end points recently suggested by the American College of Chest Physicians (ACCP) Consensus Conference on Ant...
متن کاملFondaparinux vs Enoxaparin for the Prevention of VenousThromboembolisminMajorOrthopedicSurgery
Methods: A meta-analysis of 4 multicenter, randomized, double-blind trials in patients undergoing elective hip replacement, elective major knee surgery, and surgery for hip fracture (N=7344) was performed to determine whether a subcutaneous 2.5-mg, once-daily regimen of fondaparinux sodium starting 6 hours after surgery was more effective and as safe as approved enoxaparin regimens in preventin...
متن کامل